One medicine turns acetylcholine receptors on to treat schizophrenia. Dozens of others block those same receptors as a side effect. Location decides which one happens.
Part 6 of the Brain Chemistry series. New here? Start with Your Brain Is Not a Gas Tank, the short orientation that explains the four questions every article in this series answers.
What to know
- Acetylcholine is not just a memory chemical. It helps the brain pay attention, and it runs the heart rate, gut, bladder, pupils, sweat glands, and saliva in the body.
- Acetylcholine works through two receptor families: muscarinic (M1 through M5) and nicotinic. A drug that reaches one can do something completely different from the same drug reaching the other.
- Cobenfy (xanomeline-trospium) is the first FDA-approved medicine that directly activates muscarinic receptors to treat schizophrenia. Its benefit does not prove schizophrenia is caused by low acetylcholine.
- Many other psychiatric medicines block muscarinic receptors as a side effect, not their main job. Adding several of these together raises what’s called anticholinergic burden.
- Nicotine and tobacco smoke are not the same interaction. Nicotine acts on receptors. Smoke changes a liver enzyme that affects clozapine levels. This matters even if a dose hasn’t changed.
- No blood, urine, or saliva test can measure acetylcholine activity in your brain.
The short answer
Acetylcholine is a chemical messenger with an unusually wide reach. In the brain, it helps you notice cues, learn, hold attention, and control movement. In the rest of the body, it runs your heart rate, gut movement, bladder, pupils, sweat glands, and saliva.
It works through two very different receptor types. Muscarinic receptors, labeled M1 through M5, use slower signaling and sit in the brain and throughout the body. Nicotinic receptors are fast channels that open and close quickly, and they’re what nicotine itself activates.
This is why acetylcholine medicines can look like opposites. Cobenfy, the brand name for xanomeline-trospium, activates certain muscarinic receptors in the brain to treat schizophrenia in adults. Meanwhile, a long list of other psychiatric medicines, including several antipsychotics and antidepressants, block muscarinic receptors as a secondary effect, not their main action, causing dry mouth, constipation, blurred vision, or confusion. A separate class of drugs, cholinesterase inhibitors like donepezil, slows the enzyme that breaks acetylcholine down, which can support cognition in dementia. Nicotine works at nicotinic receptors, a different system entirely, which is why it doesn’t cause the same dry-mouth, constipation type of side effects.
Acetylcholine’s reach explains why one messenger can cause such different effects.
Attention and cue detection. Brief bursts of acetylcholine in the cortex help the brain notice what’s relevant.14 Block central muscarinic receptors and attention gets harder.
Memory. Acetylcholine supports how the brain encodes new information. But memory trouble is never proof of an acetylcholine problem by itself. Sleep loss, depression, anxiety, pain, other medicines, and many medical conditions can all cause the same trouble.
Movement. Acetylcholine and dopamine interact in a brain region called the striatum. This is why some anticholinergic medicines can ease certain medication-related movement side effects, even while the same drug worsens memory or causes constipation.
Body functions. Muscarinic receptors control saliva, tears, sweating, pupil size, gut movement, bladder contraction, and heart rate. This is why side effects from acetylcholine-blocking medicines show up far from the brain.
Nicotine reinforcement. Nicotine activates nicotinic receptors directly. Repeated use changes how those receptors function, and withdrawal can bring irritability, craving, and trouble concentrating. None of that proves nicotine was correcting a real deficiency.
Two families that work in opposite directions
The same messenger can turn signaling up in one place and down in another because it acts on different receptors in different tissues.
M1 and M3 receptors usually turn cell activity up. M2 and M4 usually turn it down. Nicotinic receptors work differently altogether, opening an ion channel for a fast electrical signal instead of a slower chemical cascade. Location matters as much as receptor type: an M2 receptor in the heart can slow your pulse, while a nicotinic receptor in a different part of the nervous system does something else entirely.
| Receptor or target | What it does, where it matters most, and why you might care |
|---|---|
| M1 | What it does: Usually increases cell signaling. Where it matters most: Cortex, hippocampus. Why you might care: Central to attention and thinking; blocking it can worsen memory and confusion. |
| M2 | What it does: Usually slows cell signaling. Where it matters most: Heart, brain. Why you might care: Activating it can slow heart rate; blocking it can speed it up. |
| M3 | What it does: Usually increases cell signaling. Where it matters most: Glands, gut, bladder, eyes. Why you might care: Blocking it causes dry mouth, constipation, urinary retention, and blurred vision. |
| M4 | What it does: Usually slows cell signaling. Where it matters most: Striatum, cortex. Why you might care: Xanomeline’s main brain target; may help regulate dopamine-related circuits. |
| Nicotinic receptors | What it does: Fast ion channels. Where it matters most: Attention and reward circuits. Why you might care: The target of nicotine itself, and of smoking-cessation medicines. |
| Acetylcholinesterase | What it does: Enzyme that breaks acetylcholine down quickly. Where it matters most: Synapses throughout the brain and body. Why you might care: Slowing it with a drug can support cognition in dementia, but also cause its own side effects. |
Cobenfy: activating acetylcholine on purpose
Cobenfy is xanomeline combined with trospium, and it’s the first FDA-approved medicine that works this way for schizophrenia. Xanomeline acts in the brain, with stronger activity at the M1 and M4 receptors described above. Trospium mostly blocks muscarinic receptors outside the brain, which is meant to reduce some of xanomeline’s body-wide effects.1
Because xanomeline touches all five muscarinic receptors to some degree, and trospium’s blockade doesn’t create a perfect wall between brain and body, a person can experience both cholinergic effects (like nausea or sweating, from xanomeline reaching the brain) and anticholinergic effects (like dry mouth or constipation, from residual muscarinic blockade) at the same time. Cobenfy’s approval was based on two 5-week controlled studies in adults, and its full treatment mechanism in schizophrenia is still not completely mapped out.17 The medicine working does not mean schizophrenia is caused by an acetylcholine shortage.
Anticholinergic burden: when several medicines add up
Many psychiatric medicines block muscarinic receptors as a side effect of doing their main job elsewhere. Clozapine, olanzapine, quetiapine, some tricyclic antidepressants, and paroxetine are examples. Quetiapine’s active byproduct, norquetiapine, actually binds M1 more strongly than quetiapine itself does, according to the current label’s lab testing, though that doesn’t tell us the exact effect in any one person.10
When several of these medicines are combined, or stacked with over-the-counter sleep or allergy products (many of which also work through the separate histamine system), the combined receptor-blocking effect is called anticholinergic burden. Research finds that a higher burden is associated with worse cognition in some groups, but anticholinergic burden scales are screening aids, not proof. They disagree with each other about some medicines, and a high score on a scale doesn’t prove which specific drug caused which specific symptom in any one person. Bring your full medicine list, including over-the-counter products, to every review.
| Medicine | What it does directly, used for, and main tradeoffs |
|---|---|
| Xanomeline-trospium (Cobenfy) | What it does directly: Xanomeline activates muscarinic receptors, mainly M1 and M4, in the brain; trospium blocks them mainly outside the brain. Used for: Schizophrenia in adults. Main tradeoffs: Nausea, vomiting, constipation, dry mouth, urinary retention, heart-rate effects, and a liver-injury warning. |
| Donepezil and galantamine | What it does directly: Slow acetylcholine breakdown by blocking acetylcholinesterase. Used for: Specific dementia uses, product dependent. Main tradeoffs: Nausea, diarrhea, weight loss, slow heart rate, and fainting. |
| Rivastigmine | What it does directly: Blocks both acetylcholinesterase and a related enzyme, butyrylcholinesterase. Used for: Specific dementia uses, product dependent. Main tradeoffs: Cholinergic side effects, plus skin or stomach issues depending on the formulation. |
| Benztropine and similar central antimuscarinics | What it does directly: Block muscarinic receptors. Used for: Select medication-related movement side effects. Main tradeoffs: Memory impairment, dry mouth, constipation, urinary retention, fast heart rate, and heat illness risk. |
| Clozapine, olanzapine, quetiapine, and some antidepressants | What it does directly: Block muscarinic receptors as a secondary effect of their main action. Used for: Antipsychotic or antidepressant treatment. Main tradeoffs: Adds to anticholinergic burden; can worsen bowel, bladder, cognition, or heat tolerance. |
| Nicotine replacement products | What it does directly: Activate nicotinic receptors, more slowly than combustible cigarettes. Used for: Smoking cessation. Main tradeoffs: Nausea, sleep and cardiovascular effects that vary by product. |
| Varenicline | What it does directly: Partially activates nicotinic receptors. Used for: Smoking cessation. Main tradeoffs: Nausea, sleep changes, and vivid dreams. |
Smoke is not nicotine
This is the part of the acetylcholine story most people get backwards.
Nicotine directly activates nicotinic receptors. Combustible tobacco smoke also contains compounds that induce an entirely separate liver enzyme, CYP1A2. These are two unrelated mechanisms happening at the same time when someone smokes.
Clozapine is partly broken down by CYP1A2. Combustible smoking speeds that enzyme up, which lowers clozapine levels in the blood. If someone cuts back or stops smoking, that induction reverses, and clozapine exposure can rise even though the prescribed dose hasn’t changed at all.11 This is why any change in smoking needs to be reported to the prescriber as a medication-review event, not just a lifestyle note.
Nicotine replacement products and vaping cannot be assumed to have the same effect on this enzyme as combustible smoke. The evidence points to the combustion products themselves, not nicotine, as the driver of the interaction.12 Never adjust a clozapine dose yourself because of a smoking change. Tell the prescriber and pharmacist, so they can plan appropriate monitoring.
Separately: the FDA removed the clozapine REMS program, which was a restricted distribution and reporting system, effective June 13, 2025.13 That removal did not touch the underlying safety issue. Clozapine still carries a boxed warning for severe neutropenia, a dangerous drop in a type of white blood cell, and it still requires monitoring of absolute neutrophil count as directed by the label.13 The REMS program and the neutropenia risk are two separate things, and only one of them went away.
Can a test measure this?
Not in a way that’s useful for everyday psychiatric decisions. Research PET scans can estimate how many muscarinic or nicotinic receptors are available in a specific brain area, but that’s target-specific, tracer-dependent, and doesn’t show an overall acetylcholine level or explain a symptom. EEG, attention tasks, memory testing, and pupil measures show downstream function, not the transmitter itself.
Cholinesterase blood tests matter for specific poisonings or occupational chemical exposures, which is a different situation entirely from a commercial neurotransmitter panel marketed for psychiatric symptoms. Blood, urine, saliva, and hair cannot report what’s happening at a living brain synapse. A genetic test may answer a narrow question about how you metabolize a drug, but it doesn’t measure acetylcholine either.
Which symptoms need a call, and which need urgent help
Track and mention at your next visit: mild dry mouth, mild nausea, or a small, manageable bowel change that matches what your prescriber already told you to expect.
Call the prescriber or pharmacist promptly: new confusion, memory trouble that’s affecting daily function, constipation, trouble urinating, blurred vision, faintness, or a major change in heart rate. Also call about jaundice, dark urine, a change in your smoking habits, or starting a new over-the-counter sleep, allergy, or motion-sickness product.
Call Poison Control at 1-800-222-1222 for a suspected overdose, mixed cholinergic and anticholinergic symptoms, an accidental extra dose, or any dangerous combination.
Call 911 now for seizure, loss of consciousness, severe breathing trouble, tongue or throat swelling, collapse, or severe confusion with unsafe behavior. Also call for signs of heat stroke, or severe belly pain with vomiting and swelling. For a suicidal or mental health crisis, call or text 988. If danger is immediate, call 911.
Older adults, and people with cognitive impairment, glaucoma risk, urinary or bowel problems, heart disease, or liver or kidney disease may be more vulnerable to these effects, as can anyone taking several medicines at once. Your brain is not a gas tank, and neither dry mouth nor a memory problem is a reliable readout of what your acetylcholine level is doing.
What to ask your prescriber
These are conversation starters, not instructions.
- Which symptom or function is this medicine meant to improve?
- Is its acetylcholine action its main job, or a secondary effect?
- Which muscarinic or nicotinic receptor matters most for this drug?
- Could my whole regimen add up to meaningful anticholinergic burden?
- Do any of my over-the-counter sleep, allergy, or motion-sickness products add to that burden?
- What monitoring fits my bowel, bladder, eye, heart, liver, or cognitive history?
- Could a change in my smoking alter how this medicine works in my body?
- What should I do if I miss a dose?
- How will we decide whether the benefit is worth continuing?
Bottom line
Acetylcholine does not run on a single dial that’s simply too high or too low. It works through two separate receptor families spread across the brain and body, which is exactly why one medicine can treat schizophrenia by activating those receptors while dozens of others cause dry mouth and constipation by blocking the same receptor family elsewhere. Memory trouble is not proof of an acetylcholine deficiency, and a side effect is not proof a medicine is working. Ask what a medicine touches directly, watch for the warning signs above, and never adjust anticholinergic medicine, or report a smoking change, without your prescriber.
Frequently asked questions
Does poor memory mean I have low acetylcholine?
No. Memory problems have many causes, including sleep, mood, other medical conditions, and other medicines. Even in Alzheimer disease, acetylcholine is only one part of a much larger disease process.
If Cobenfy works on acetylcholine, does that mean schizophrenia is an acetylcholine disorder?
No. A medicine working at a target doesn’t prove that target caused the illness. Cobenfy changes muscarinic signaling and the downstream circuits connected to it, but the complete chain from that change to symptom relief is still not fully known.
Does dry mouth mean my medicine is working?
No. Dry mouth is a side effect from muscarinic receptors in your glands. It doesn’t measure whether the medicine is achieving its intended psychiatric benefit.
Is nicotine the reason smoking changes clozapine levels?
No. Nicotine acts on nicotinic receptors. It’s the combustion products in tobacco smoke that change a liver enzyme called CYP1A2. That distinction is exactly why vaping and nicotine replacement can’t be assumed to behave the same way.
Can a urine test measure my brain’s acetylcholine?
No. A sample from outside the brain can’t report what’s happening at a living attention or memory circuit inside it.
Why can an anticholinergic medicine help a movement side effect but worsen my thinking?
The same drug can quiet acetylcholine signaling in a movement circuit in the brain while also blocking receptors in memory circuits and in organs like the gut and bladder, all at once.
What is anticholinergic burden, exactly?
It’s the combined receptor-blocking effect of every relevant medicine you take together. The total regimen can matter more than any single drug, but burden scores are screening aids, not proof that one specific drug caused one specific symptom.
Related reading on NP FADY
- Your Brain Is Not a Gas Tank (start here)
- The Allergy Chemical That Keeps You Awake
- Why Two Opposite Medicines Both Target Dopamine
- Antidepressant Side Effects No One Warned Me About and How to Manage Them
References
1. Xanomeline-trospium (Cobenfy) prescribing information. DailyMed. Accessed August 31, 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8f0e73bf-6025-44f6-ab64-0983322de0df
2. Cholinergic receptor review. PMC. Accessed August 31, 2026. https://pmc.ncbi.nlm.nih.gov/articles/PMC7058246/
3. Systematic review of anticholinergic burden and cognition in schizophrenia. PMC. Accessed August 31, 2026. https://pmc.ncbi.nlm.nih.gov/articles/PMC8748260/
4. Observational cognition study of anticholinergic exposure. PMC. Accessed August 31, 2026. https://pmc.ncbi.nlm.nih.gov/articles/PMC8440496/
5. TC-5619 alpha7 nicotinic agonist trial in schizophrenia (null result). PubMed. Accessed August 31, 2026. PMID: 26071208
6. FDA approves drug with new mechanism of action for treatment of schizophrenia (Cobenfy approval announcement). FDA. Accessed August 31, 2026. https://www.fda.gov/news-events/press-announcements/fda-approves-drug-new-mechanism-action-treatment-schizophrenia
7. FDA Drug Trials Snapshot: Cobenfy. FDA. Accessed August 31, 2026. https://www.fda.gov/drugs/drug-trials-snapshots/drug-trials-snapshot-cobenfy
8. Donepezil prescribing information. DailyMed. Accessed August 31, 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=76bf638e-dbde-418e-8977-1caf009990bc
9. Rivastigmine butyrylcholinesterase-inhibition supplement approval letter. FDA. Accessed August 31, 2026. https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2013/020823Orig1s009%2Cs027%2Cs028%2Cs029%2C021025Orig1s018%2Cs019%2Cs0020ltr.pdf
10. Quetiapine prescribing information, including norquetiapine active-metabolite receptor-binding data. DailyMed. Accessed August 31, 2026. https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=9f927ae2-a0ae-4953-99ba-8de59ee5bfca
11. Clozapine prescribing information, including CYP1A2 and tobacco-smoke interaction labeling. DailyMed. Accessed August 31, 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d5c8a456-6f3c-4963-b321-4ed746f690e4
12. Prospective study of a smoking ban and its effect on clozapine levels. PMC. Accessed August 31, 2026. https://pmc.ncbi.nlm.nih.gov/articles/PMC5315231/
13. FDA removes Risk Evaluation and Mitigation Strategy (REMS) program for the antipsychotic drug clozapine. FDA safety communication. Accessed August 31, 2026. https://www.fda.gov/drugs/drug-safety-communications/fda-removes-risk-evaluation-and-mitigation-strategy-rems-program-antipsychotic-drug-clozapine
14. Cortical acetylcholine neuromodulation review. PMC. Accessed August 31, 2026. https://pmc.ncbi.nlm.nih.gov/articles/PMC3466476/
This article is general education. It is not a diagnosis or a treatment plan. Do not start, stop, or change a medicine because of something you read here. Review every prescription, supplement, and substance with your prescriber or pharmacist.
If you or someone you know is in crisis
- Call 911 or go to your nearest emergency room for any life-threatening emergency.
- 988 Suicide & Crisis Lifeline — call or text 988, available 24/7. En español: marque 988 y oprima 2. Veterans: 988 and press 1, or text 838255.
- Crisis Text Line — text HOME to 741741.
- The Trevor Project (crisis support for LGBTQ+ young people) — call 1-866-488-7386, or text START to 678-678.
- National Sexual Assault Hotline (RAINN) — call 1-800-656-HOPE (4673) or text HOPE to 64673; free, confidential, 24/7. Online chat at RAINN.org/hotline.
- National Domestic Violence Hotline — call 1-800-799-SAFE (7233) or text START to 88788; 24/7, help in 200+ languages. Online chat at TheHotline.org. If your phone or computer may be monitored, calling from a safer device is an option.
- Riverside County — Inland SoCal Crisis Helpline 951-686-HELP (4357), 24/7 (Inland SoCal United Way / 211+, in partnership with RUHS-BH); Community Access, Referral, Evaluation and Support (CARES) Line 800-499-3008, 24/7.
- San Bernardino County — Access Unit (Behavioral Health Helpline) 888-743-1478, 24/7; Mobile Crisis/CCRT 800-398-0018 (24/7, all ages) or text 909-420-0560. Arrowhead Regional Medical Center (ARMC) has a dedicated walk-in adolescent psychiatric ER (ages 13–17).
- Children under 13 — call 911 for immediate danger, contact your county's mobile crisis team (they respond to all ages), or go to the nearest pediatric emergency room.
- California Peer-Run Warm Line (non-crisis — someone to talk to) — call or text 1-855-600-WARM (9276); daytime and evening hours, not a 24/7 line.
- NP Fady (non-emergency) — for routine scheduling or questions, call (909) 707-6261. This line is not monitored for emergencies.